Publicacions
El coneixement generat a IrsiCaixa es comparteix amb la comunitat científica a través de la publicació d’articles a revistes científiques d’alt impacte.
![Imatge de Publicacions](/sites/default/files/styles/3_1_small/public/2022-11/Portada_publicacions-petita_0.jpg?h=c6980913&itok=oZMso2V6)
A novel TaqMan real-time PCR assay to estimate ex vivo human immunodeficiency virus type 1 fitness in the era of multi-target (pol and env) antiretroviral therapy.
Anti-HIV-1 activity of enfuvirtide (T-20) by inhibition of bystander cell death.
Genetic screen for monitoring hepatitis C virus NS3 serine protease activity.
Reduced fitness of HIV-1 resistant to CXCR4 antagonists.
Influence of human immunodeficiency virus type 1 subtype on mother-to-child transmission.
Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine.
Anti-HIV activity of a novel aminoglycoside-arginine conjugate.
Quality of life, emotional status, and adherence of HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens.
Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity.
RNA interference of HIV replication.